Shares of Kura Oncology Inc. (NASDAQ:KURA) were up 2.4% on Tuesday . The company traded as high as $5.24 and last traded at $5.20, with a volume of 57,165 shares. The stock had previously closed at $5.08.

A number of analysts have weighed in on KURA shares. Zacks Investment Research cut shares of Kura Oncology from a “buy” rating to a “hold” rating in a report on Tuesday, May 17th. Oppenheimer Holdings Inc. reissued an “outperform” rating and set a $16.00 price objective on shares of Kura Oncology in a report on Tuesday, June 21st.

The company’s 50-day moving average price is $4.22 and its 200 day moving average price is $3.66. The firm’s market cap is $102.90 million.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Wednesday, August 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.02. Equities analysts predict that Kura Oncology Inc. will post ($1.58) earnings per share for the current fiscal year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.